CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel therapeutic agent called Anticalin, designed to target hepcidin, a key regulator of iron levels. It aims to treat anemia of chronic disease by neutralizing hepcidin, potentially improving patient responses to existing anemia treatments while minimizing side effects.
The consortium aims to develop and produce an Anticalin, a member of a novel high-affinity scaffold derived from the lipocalin protein family.
The Anticalin is specific for hepcidin which is a central regulator of iron homeostasis, and will be used to antagonize hepcidin for the treatment of “anemia of chronic disease” (ACD).
Anticalins are genetically modified lipocalins that can target almost any desired molecule.
Unlike Immunoglobulins, they can be produced at low cost in microbial expression…
PIERIS PHARMACEUTICALS GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Muenchen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Austria, Innsbruck
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
STICHTING RADBOUD UNIVERSITEIT
Netherlands, Nijmegen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Harrogate
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
